Welcome to our dedicated page for Cassava Sciences SEC filings (Ticker: SAVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cassava Sciences� quest to treat Alzheimer’s produces dense scientific disclosures that can leave even seasoned investors hunting for answers. Finding trial updates, cash-runway details, or spotting when executives buy more shares often means combing through hundreds of pages and multiple form types.
Stock Titan turns that problem on its head. Our AI parses every Cassava Sciences annual report 10-K simplified, highlights clinical milestones inside each quarterly earnings report 10-Q filing, and flags Cassava Sciences Form 4 insider transactions real-time—minutes after they reach EDGAR. Whether you are asking “How do I read Cassava Sciences� 10-K?� or searching for “Cassava Sciences proxy statement executive compensation,� the answers surface instantly in plain English summaries.
Coverage spans every filing: 8-K material events explained for trial results, S-3 shelf registrations that hint at future capital raises, and the definitive proxy where stock-based pay is outlined. Investors track:
- R&D spending trends without wading through accounting footnotes
- Cash-burn projections derived from Cassava Sciences earnings report filing analysis
- Phase 3 timeline disclosures within risk-factor sections
- Cassava Sciences executive stock transactions Form 4 that signal insider confidence
Still comparing data manually? With understanding Cassava Sciences SEC documents with AI, you can monitor “Cassava Sciences insider trading Form 4 transactions,� set alerts for each new Cassava Sciences 8-K, and get Cassava Sciences SEC filings explained simply—so you spend time making decisions, not decoding jargon.
Cassava Sciences (SAVA) filed an 8-K to disclose positive preclinical data for simufilam in tuberous sclerosis complex (TSC)-related epilepsy. In a Tsc1 conditional knockout mouse model that develops spontaneous seizures, multiple doses of simufilam were tested over ~3 weeks. The compound significantly reduced seizure progression in a dose-dependent manner; other measured endpoints did not reach significance.
The study was run with the TSC Alliance and PsychoGenics under the TSC Preclinical Consortium. Management plans to present full data at a scientific meeting and initiate the first human proof-of-concept trial in H1 2026. No financial terms, revenue impact, or guidance were provided. Item 7.01 makes the accompanying press release furnished, not filed.
Key takeaways:
- Preclinical efficacy signal supports simufilam’s mechanism beyond Alzheimer’s.
- Expands pipeline into rare-disease epilepsy market.
- Tight timeline sets a near-term catalyst but still carries high development risk.
The Vanguard Group filed Amendment No. 10 to Schedule 13G on 29 Jul 2025, disclosing its passive ownership of Apple Inc. (AAPL) as of 30 Jun 2025.
Vanguard beneficially owns 1,415,826,462 Apple common shares, representing 9.47 % of the outstanding class. It reports 0 shares with sole voting power and 19,800,347 shares with shared voting power, while holding sole dispositive power over 1,343,278,627 shares and shared dispositive power over 72,547,835 shares.
The firm qualifies as an investment adviser under Rule 13d-1(b)(1)(ii)(E) and certifies the holdings were acquired in the ordinary course of business, with no intent to influence Apple’s control. No additional material transactions or strategic intentions are noted.
Guidewire Software, Inc. (GWRE) � Form 144 Notice of Proposed Sale
An individual affiliate intends to sell 1,000 Class A common shares through UBS Financial Services on or about 24 June 2025. The shares are valued at an aggregate $238,000, implying an average reference value of roughly $238 per share. Compared with the company’s 84.195 million shares outstanding, the planned sale represents only 0.0012 % of the float, indicating no material dilution or change in control.
The filer previously acquired 2,000 shares in an open-market cash purchase on 15 June 2022. During the past three months, the same insider—identified as Michael C. Keller—s´Ç±ô»ĺ 860 shares on 16 June 2025, generating $218,836 in gross proceeds (â‰� $254 per share). All representations affirm the seller is unaware of undisclosed adverse information, in accordance with Rule 144 and Rule 10b5-1 requirements.
Because the transaction size is immaterial relative to GWRE’s market capitalization and share count, the filing is largely administrative. Nevertheless, it signals incremental insider liquidity activity investors may monitor for trend development.
FAQ
What is the current stock price of Cassava Sciences (SAVA)?
What is the market cap of Cassava Sciences (SAVA)?
What is the primary focus of Cassava Sciences?
What are the main product candidates being developed?
In which stage of development is Cassava Sciences currently operating?
How does Cassava Sciences differentiate itself in the biotech industry?
What regulatory considerations affect the company?
How does the company approach research and development?
Can you explain the significance of early diagnostic testing in their work?
What challenges are typically encountered by companies at this development stage?
